Choi Hyeryeon, Kim Kwangsoon
Department of Surgery, Eulji Medical Center, Eulji University School of Medicine, Seoul 01830, Republic of Korea.
Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Diagnostics (Basel). 2023 Jan 11;13(2):272. doi: 10.3390/diagnostics13020272.
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with poor prognosis. Current endocrine therapy or anti HER-2 therapy is not available for these patients. Chemotherapeutic treatment response varies among patients due to the disease heterogeneity. To overcome these challenges, theranostics for treating TNBC have been widely investigated. Anticancer material conjugated nanoparticles with target-binding ligand and tracer agents enable simultaneous drug delivery and visualization of the lesion with minimal off-target toxicity. In this review, we summarize recently FDA-approved targeted therapies for TNBC, such as poly-ADP-ribose polymerase (PARP) inhibitors, check point inhibitors, and antibody-drug conjugates. Particularly, novel theranostic approaches including lipid-based, polymer-based, and carbon-based nanocarriers are discussed, which can provide basic overview of nano-therapeutic modalities in TNBC diagnosis and treatment.
三阴性乳腺癌（TNBC）是一种侵袭性乳腺癌亚型，预后较差。目前这些患者无法接受内分泌治疗或抗HER-2治疗。由于疾病的异质性，化疗治疗反应在患者之间存在差异。为了克服这些挑战，用于治疗TNBC的诊疗一体化技术已得到广泛研究。与靶向结合配体和示踪剂共轭的抗癌材料纳米颗粒能够在实现药物递送的同时，以最小的脱靶毒性实现病灶可视化。在这篇综述中，我们总结了美国食品药品监督管理局（FDA）最近批准的用于TNBC的靶向治疗方法，如聚ADP核糖聚合酶（PARP）抑制剂、检查点抑制剂和抗体药物偶联物。特别地，还讨论了包括基于脂质、基于聚合物和基于碳的纳米载体在内的新型诊疗一体化方法，这些方法可以为TNBC诊断和治疗中的纳米治疗模式提供基本概述。
